Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients.
about
Physiogenomic comparison of human fat loss in response to diets restrictive of carbohydrate or fatAcetyl-coenzyme A carboxylase alpha gene variations may be associated with the direct effects of some antipsychotics on triglyceride levelsPhysiogenomic analysis of localized FMRI brain activity in schizophrenia.Physiogenomic analysis of the Puerto Rican population.Protection from olanzapine-induced metabolic toxicity in mice by acetaminophen and tetrahydroindenoindole.Leptin gene -2548G/A variants predict risperidone-associated weight gain in children and adolescents.Physiogenomic analysis of statin-treated patients: domain-specific counter effects within the ACACB gene on low-density lipoprotein cholesterol?Physiogenomic analysis of CYP450 drug metabolism correlates dyslipidemia with pharmacogenetic functional status in psychiatric patients'Generic to genetic' transition in cardiovascular and neuropsychiatric drugs: opportunity for personalized medicine.Genomas: battling side effects with physiotypes.Association of common genetic variants with risperidone adverse events in a Spanish schizophrenic population.Validation of candidate genes associated with cardiovascular risk factors in psychiatric patients.Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin.Refractory restless legs syndrome likely caused by olanzapinePharmacogenetics of leptin in antipsychotic-associated weight gain and obesity-related complicationsPersonalized medicine for diabetes.Associations between the -2548G/A Promoter and Baseline Weight and between Gln223Arg and Lys656Asn Variants and Change in BMI Scores in Arab Children and Adolescents Treated with Risperidone
P2860
Q21093205-5D7695D8-A9FF-4D4D-B4E3-58F2525567D7Q24649745-B70AEC51-B62E-4B55-AC3E-3CCCCA91EB66Q30490136-78C3380B-DA49-4030-94A1-4154A49CF783Q33758504-7F6EA305-CB2E-4BAB-9E39-56CB36963571Q33912482-3163504C-FD54-487E-9C9E-E79B1B8B41C7Q34056408-9B43EA3E-0F9F-439D-A338-5828B72099C9Q34066977-7B698EE7-2C0D-4B5F-9343-C3B4DB4F6487Q35575577-485699B4-B146-45AB-AE7A-D300178EB2F4Q36421538-313556C9-BDCE-43B9-9ED4-EDF3312CE97BQ36594548-F8F6C3FF-05C4-472E-94A7-7CC19E4CA01AQ36747019-A53F8CB5-5A49-4933-93DF-D158BBB97D26Q37016538-56311AD1-2852-409A-ABCB-1E97AA1AD780Q37060706-C48072B0-7AB2-4EDB-9044-4B24BEA06C26Q37086884-54573C5B-EB31-4932-AC43-EAD0119379D7Q37220366-A94709C7-26EB-4470-9888-3957EB6BA921Q42598608-DDCAC662-B624-4EE7-AF7A-5C7F4BB033B0Q58598653-C1568880-DA62-41A6-AB51-A72A329C06AD
P2860
Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Physiogenomic comparison of we ...... risperidone-treated patients.
@en
type
label
Physiogenomic comparison of we ...... risperidone-treated patients.
@en
prefLabel
Physiogenomic comparison of we ...... risperidone-treated patients.
@en
P2093
P2860
P356
P1433
P1476
Physiogenomic comparison of we ...... risperidone-treated patients.
@en
P2093
A Windemuth
J W Goethe
M Kocherla
T R Holford
P2860
P2888
P304
P356
10.1038/SJ.MP.4001944
P407
P577
2007-01-02T00:00:00Z